...
Breaking news this morning has all eyes on (ATNM) ahead of the opening bell.

StockWireNews

Breaking News Could Trigger A Massive Breakout For (ATNM) This Morning (Strong Green Surge In Pre-Market)

October 31st

Greetings Readers,

Breaking news this morning has all eyes on (ATNM) ahead of the opening bell.

Check it out:

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001

NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a conditioning regimen prior to a Bone Marrow Transplant (BMT) versus a control arm which allowed all current means of conventional care with the intent to transplant these patients. The SIERRA trial met its primary endpoint of durable complete remission or dCR of 6 months post initial remission after a BMT in Iomab-B arm compared to conventional care arm demonstrating statistical significance p<0.0001.

...

Read the full article here.

This is a huge milestone for ATNM, and if you haven't noticed yet, this profile is surging during pre-market.

At the time of writing this update, ATNM is trading up approximately 25% over $12.00+.

Don't waste a second to get ATNM on your radar this morning.

-----

It's Monday morning and the opening bell awaits us. Let's get straight to it.

We've had an October to remember. Over and over again, we've delivered breakout ideas right to your doorstep:

  • Last week, our Friday Nasdaq profile surged approximately 17% intraday from an open of $1.30 to a 3-month high of $1.50.
  • The day before? My alert ran approximately 13% intraday from an open of $2.83 to a high of $3.22.
  • Wednesday (10/26)'s profile? Approximately 10% from an open of $.30 to a high of $.33.
  • And to get the party started, Monday's profile. From an open of $2.55 to a high of $3.29, it ran approximately 29% intraday.

4 double-digit champs run approximately 69% combined.

And in only one week!

But it's best to look forward to Monday... and what could be.

While monitoring the Nasdaq markets towards the end of last week, I also watched the NYSE American market and this is what I found.

Based on its low float, a new $20 analyst price target, bullish technical indicators, and topline data coming in Q4, this Biopharma needs top spot on your watch-list this week.

For Monday, October 31st, get this company on your radar:

*Actinium Pharmaceuticals, Inc. (ATNM)*

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.

And ATNM has 4 potential catalysts to pay attention to right now. Check them out:

No. 1 - Bullish Triggered Technicals Galore

No. 2 - Low Float Volatility Possible On Daily Basis

No. 3 - Cantor Fitzgerald Initiates Coverage With $20 Target

No. 4 - Company Update Presents A Possibly Mind-Blowing Q4

But more on those in a second...

-----

There is Demand For a Leukemia Cure... and the Market Looks Lucrative

The leukemia therapeutics market could reach $17.1Bn by 2024 from $12.3Bn in 2019, at a CAGR of 6.8%.

image

Do you know what’s driving this market?

A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The increasing number of approvals of novel & innovative dr-ugs and immunotherapies is evidence of an increasing need for leukemia therapies.

Say hello to a wide-open opp. for Actinium Pharmaceuticals (ATNM).

Treatment options for AML, or acute myeloid leukemia, is precisely an unmet need- especially for those under 45. According to Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, as quoted by Check Rare, it is rarely diagnosed in patients under the age of 45. (1)

At the moment, the five-year survival rate for those 20 and older is also putrid 26%. (2)

Some must also contend with relapsed, or recurrent, acute myelogenous leukemia (AML), which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. (3)

Actinium’s Iomab-B Could Be Nearing a Treatment With SIERRA trials

image

On September 15, 2021, Actinium announced enrollment for its pivotal Phase III SIERRA trial of Iomab-B was complete.

SIERRA is a 153-patient, multicenter, randomized trial studying Iomab-B, an antibody-radiation conjugate comprising an anti-CD45 antibody and radioactive iodine-131 (I-131), compared with salvage chemotherapy inactive, relapsed, or refractory acute myeloid leukemia (AML).

Iomab-B was developed to address the significant unmet need of patients who could benefit and possibly be cured of their blood cancer with a bone marrow transplant but could not receive a transplant because non-targeted conditioning regimens could not produce a remission or are too toxic in this patient population. We are confident that Iomab-B will squarely address this unmet need given its targeted nature and ability to deliver high amounts of radiation directly to the bone marrow resulting in myeloablation while sparing healthy organs,” said Dr. Avinash Desai, Actinium Pharmaceuticals’ Executive VP, Clinical Development. (4)

image

The company’s Chief Medical Officer, Avinash Desai said:

The remarkably consistent and high rates of BMT engraftment together with the low rates of non-relapse transplant-related mortality at day 100 with Iomab-B through 100% enrollment give us great confidence in SIERRA.

image

In short, if things continue progressing the way they are and Q4 topline data is impressive, Actinium Pharmaceuticals (ATNM) could become a game-changer.

Read the company presentation here.

-----

And as I mentioned above ATNM has 5 potential catalysts to know right now. Here they are:

No. 1 ATNM Potential Catalyst - Bullish Triggered Technicals Galore

I'm telling you right now... Don't discount ATNM's technical indicators.

At close on Friday, ATNM was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these technical indicators as triggered:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

The website also shares its all-important "TrendSpotter" composite indicator is triggered too.

Could this be a signal that ATNM is only starting to heat up after a recent green move last week?

-----

No. 2 ATNM Potential Catalyst - Low Float Volatility Possible On Daily Basis

According to the Yahoo Finance website, ATNM has a low float.

The website reports this profile to have approximately 24.29Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news (like Q4 topline data) help provide a near term spark?

-----

No. 3 ATNM Potential Catalyst - Cantor Fitzgerald Initiates Coverage With $20 Target

Last month, fi-nan-cial services company, Cantor Fitzgerald, tagged ATNM with a $20 target.

That provides this NYSE American profile with over 100% potential upside from its closing valuation Friday.

Here's some highlights from the Yahoo Finance article:

  • The analyst believes that the SIERRA trial is the only randomized Phase 3 study that offers BMT as a treatment option for patients with active r/r Acute Myeloid Leukemia (AML).
  • "We think it is essential to focus on a 'Goldilocks' approach in finding a dose/regimen that balances safety and efficacy," the analyst writes.
  • The potential expansion of Iomab-B may also go beyond CD45 space, considering conditioning remains an integral part of adoptive cell therapies.
  • "Actinium has already achieved proof of concept in some of these settings. We think this could dramatically expand the market opportunity and open the door for further partnerships, " Cantor writes.

-----

No. 4 ATNM Potential Catalyst - Company Update Presents A Possibly Mind-Blowing Q4

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones

  • On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022
  • Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022
  • Additional updates on collaborations and pipeline progress demonstrating Actinium's leadership in the development of Actinium-225-based radiotherapies expected by year-end
  • Approximately $116Mn in cash and cash equivalents at the end of Q2 2022 expected to fund key value creating clinical, regulatory and R&D milestones through mid-2025

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today provided a business update and outlook, highlighting upcoming clinical milestones. Key milestones expected before year-end include: topline results for the pivotal Phase 3 SIERRA trial for Iomab-B; survival data from the Actimab-A CLAG-M trial; and additional updates related to progress with the Company's collaborations and internal research programs.

"Actinium is on track to deliver topline clinical results from our pivotal Phase 3 SIERRA trial for Iomab-B in the fourth quarter of this year. Iomab-B represents a potential paradigm change in the way difficult to treat relapsed or refractory (r/r) acute myeloid leukemia (AML) patients with active disease can be treated with a potentially curative bone marrow transplant (BMT)," said Sandesh Seth, Chairman and CEO of Actinium. "Iomab-B enables elderly AML patients who are relapsed or refractory to current therapies access to a bone marrow transplant without being in remission whereas current conditioning regimens require patients to be in remission. If successful, SIERRA trial results will demonstrate both improved access and outcomes in transplanted patients who currently survive just a few months as they are not treatable with currently available drugs and cannot be transplanted. Over time, Iomab-B which has been tested in multiple, hard-to-treat blood cancers, has the potential to become a universal conditioning regimen that can improve access and outcomes compared to current non-targeted conditioning regimens for hematological malignancies."

"In addition to the impending pivotal trial results, we look forward to presenting survival data from the Actimab-A CLAG-M combination trial in Q4 2022. Prior results demonstrated a 67% ORR and high rates of MRD negativity in heavily pre-treated fit patients with r/r AML. Actinium also anticipates providing updates by year-end which will demonstrate the progress we are making with our research programs and collaborations, including our Iomab-ACT program for conditioning prior to CAR-T and other cellular therapies. Finally, our strong balance sheet provides ample runway through mid-2025 which enables us to deliver value creation driven by key clinical data, regulatory milestones and R&D program advancement. These updates will enable Actinium to continue to demonstrate its position as the leading, late-stage radiotherapeutics company developing highly differentiated product candidates in diseases with high unmet or underserved medical needs," added Mr. Seth.

...

Read the full article here.

-----

ATNM Recap - 4 Potential Catalysts Could Provide A Breakout Spark

No. 1 - Bullish Triggered Technicals Galore

No. 2 - Low Float Volatility Possible On Daily Basis

No. 3 - Cantor Fitzgerald Initiates Coverage With $20 Target

No. 4 - Company Update Presents A Possibly Mind-Blowing Q4

-----

Coverage is officially initiated on ATNM. When time permits, do this:

image

Get ATNM on your radar now.

Sincerely,

Kai Parker

StockWireNews


Source 1
Source 2
Source 3
Source 4


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/28/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 3/5/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 11/5/20 and ending on 11/6/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 3/24/21 and ending on 3/26/21 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews (SWN) has been hired for a period beginning on 10/30/22 and ending on 11/01/22 to publicly disseminate information about (ATNM) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of one hundred and fifty-five thousand USD via bank wire transfer to disseminate information about (ATNM). A member of SWN Media LLC is also a member of TD Media LLC. lifewatermedia.com/atnm-disclosure-29/